Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Trametinib + paclitaxel is a combination therapy investigated by Memorial Sloan Kettering Cancer Center for the treatment of anaplastic thyroid cancer (ATC). Trametinib is an orally bioavailable, small molecule, highly selective allosteric inhibitor of mitogen-activated protein kinase kinase 1 (MEK1) and MEK2, which are key components of the MAPK/ERK signaling pathway often dysregulated in thyroid cancers. Paclitaxel is a taxane-based chemotherapy agent that stabilizes microtubules, preventing their disassembly and thereby inhibiting cell division (mitosis). This specific combination was evaluated in a Phase 2 pilot study (NCT03085056) to assess its safety and efficacy in patients with metastatic or locoregional ATC, aiming to provide a therapeutic option for a disease with a very poor prognosis. While trametinib is FDA-approved in combination with dabrafenib for BRAF V600E-mutant ATC, this regimen explores its utility with cytotoxic chemotherapy.
- Brand names
- MekinistTaxol
- Other names
- trametinib dimethyl sulfoxidepaclitaxel
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)TUBB (Tubulin (alpha and beta subunits))MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on trametinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + paclitaxel.